FluxMPS™ RPMI 1640, High Glucose + 25mM HEPES w/o Glutamine, Bicarbonate, Phenol Red

FluxMPS™ RPMI 1640, High Glucose + 25mM HEPES w/o Glutamine, Bicarbonate, Phenol Red

An MPS-grade, ready-to-use 1× RPMI 1640 medium with 4500 mg/L D-glucose, 25 mM HEPES and sodium pyruvate — supplied without L-glutamine, sodium bicarbonate or phenol red. Quadruple-stage sterile filtration (0.1 µm membrane twice, 0.04 µm membrane twice) delivers a low-particulate, mycoplasma-reduced fluid engineered for microfluidic channels, organ-on-a-chip devices and demanding suspension and adherent cultures.

• 0.04 µm final-pass filtration for ultra-low particulate, microchannel-safe fluidics
• Quadruple-stage sterile filtration: 0.1 µm ×2 + 0.04 µm ×2 (mycoplasma-reduced; smallest mycoplasma ≈ 0.2 µm)
• Endotoxin specification: NMT 5 EU/mL (BET)
• High glucose (4.5 g/L) + 25 mM HEPES; bicarbonate-free and phenol-red-free formulation
• L-glutamine-free for user-defined glutamine/GlutaMAX supplementation and stable shelf life
• HEPES buffering supports closed and limited-CO₂ microfluidic systems
• Manufactured under ISO 13485-certified, CE-approved facilities; final QC at Diagnocine, Totowa NJ
• pH/glucose/salts/HEPES and nutrient composition customizable on request

Engineered where standard media reach their limits

Conventional 0.22 µm-filtered media can still carry sub-visible particulates and the smallest mycoplasma forms (≈0.2 µm). In microfluidic channels and organ-on-a-chip devices, such particulates accumulate at junctions, foul sensors and corrupt optical readouts. FluxMPS™ RPMI 1640 finishes with a 0.04 µm polishing pass, removing particulates and mycoplasma-scale bodies that a single 0.22 µm filter leaves behind^[8].

Quadruple-stage filtration system

Every lot is sterilized through a quadruple-pass membrane train — 0.1 µm twice plus 0.04 µm twice — rather than a single 0.22 µm pass. Because the smallest mycoplasma forms measure roughly 0.2 µm, the 0.04 µm final membranes provide a mycoplasma-reduction barrier well below that size.

1. 01

   0.1 µm Pre-filtration I

   First 0.1 µm membrane pass removes large particulates and aggregates and extends downstream filter life.

2. 02

   0.04 µm Pre-filtration II

   First 0.04 µm membrane pass retains fine particulates, bacteria and mycoplasma-scale bodies.

3. 03

   0.1 µm Sterile-filtration I

   Second 0.1 µm membrane pass provides redundancy and further reduces fine particulate burden.

4. 04

   0.04 µm Sterile-filtration II — Final Polish

   Second 0.04 µm membrane delivers the ultimate sterile polish and the mycoplasma-reduction barrier (< 0.2 µm).

From microphysiological systems to classic culture

The bicarbonate-free, HEPES-buffered, high-glucose formulation suits both next-generation microphysiological platforms and the lymphocyte, hybridoma and carcinoma cultures RPMI 1640 was designed for^[1].

Automated Bioreactors & Robotics

For automated perfusion bioreactors and liquid-handling robotics, an optional 0.01 µm (10 nm) ultra-filtered grade of this medium can be produced on request to further reduce subvisible particulates that challenge fine valves and inline sensors.

• Total particulate exclusion for narrow fluidic paths
• Valve & sensor protection in unattended runs
• Extended perfusion stability between feeds

Inquiry Required: the 0.01 µm (10 nm) grade is made to order — contact support@diagnocine.com.

Technical specifications

All values reflect the product Certificate of Analysis basis at 1× concentration.

Full composition (mg/L)

Complete RPMI 1640 high-glucose formulation as released per lot. Ingredient names and mg/L values are reproduced from the product specification; CAS numbers are added for reference where established.

Manufacturing & compliance

Produced under ISO 13485-certified, CE-approved supplier facilities, with final packaging, quality assurance and testing at the Diagnocine R&D and Quality Testing Center; customization and assembly at Diagnocine Precision, Totowa, New Jersey, USA.

How DCP-RPMIGH-QBR1X compares

Versus conventional single-pass 0.22 µm-filtered RPMI 1640 formulations.

Frequently asked questions

Common questions about formulation, filtration and handling.

Supporting literature

Peer-reviewed literature relevant to RPMI 1640, HEPES buffering, organ-on-a-chip culture and mycoplasma control.

1. Moore GE, Gerner RE, Franklin HA. Culture of normal human leukocytes. JAMA. 1967;199(8):519-524. doi:10.1001/jama.1967.03120080053007
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760-772. doi:10.1038/nbt.2989
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. doi:10.1126/science.1160809
4. Good NE, Winget GD, Winter W, et al. Hydrogen ion buffers for biological research. Biochemistry. 1966;5(2):467-477. doi:10.1021/bi00866a011
5. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov. 2015;14(4):248-260. doi:10.1038/nrd4539
6. Huh D, Matthews BD, Mammoto A, et al. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662-1668. doi:10.1126/science.1188302
7. Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211-218. doi:10.1016/j.tibs.2015.12.001
8. Drexler HG, Uphoff CC. Mycoplasma contamination of cell cultures: incidence, sources, effects, detection, elimination, prevention. Cytotechnology. 2002;39(2):75-90. doi:10.1023/A:1022913015916
9. Eagle H. Amino acid metabolism in mammalian cell cultures. Science. 1959;130(3373):432-437. doi:10.1126/science.130.3373.432
10. Zhang B, Korolj A, Lai BFL, Radisic M. Advances in organ-on-a-chip engineering. Nat Rev Mater. 2018;3:257-278. doi:10.1038/s41578-018-0034-7